Anthony David Baxter

Imperial Chemical Industries Ltd. manufactures chemicals and paint products. Its products include coatings, adhesives, starch, and synthetic polymer. The company was founded on December 7, 1926 and is headquartered in Slough, the United Kingdom.

Charles River Discovery Research Services UK Ltd. provides drug discovery products and services to various pharmaceutical companies. It focuses on three areas such as kinases, G-protein coupled receptors, and ion channels. The company was founded in 1997 and is headquartered in Kent, the United Kingdom.

Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA.

Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Oxford Semiconductor Ltd. provides silicon and software solutions for personal storage and consumer connectivity. The company offers USB host, peripheral and on-the-go controller ICs and provides consumer electronics manufacturers with the complete solutions for implementing USB into their embedded systems. Oxford Semiconductor was founded by Jalil Oraee in 1992 and is headquartered in Abingdon, UK.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Biofocus, Inc. operates as a clinical biotechnology company. The company is headquartered in the United Kingdom.

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

Dotmatics Ltd. engages in the provision of informatics solutions and services. It offers antibody discovery, biologics discovery, CAR-T cell therapy, chemicals and materials innovation, data intelligence, collaborative research, decision support, laboratory informatics, and small molecule discovery solutions. The firm also provides bioregister, browser, cascade, chemselector, cloud, D4O, elemental, gateway, inventory, nucleus, and pinpoint. The company was founded by Stephen Christian Gallagher and Alastair William Hill on November 7, 2005 and is headquartered in Bishops Stortford, the United Kingdom.

Adroit Digital is a company that provides digital advertising programs. The company is based in New York, NY. The CEO of the company is Richard Lingard.

Part of Charles River Laboratories International, Inc., Argenta Discovery 2009 Ltd. offers contract research drug discovery services. The company is based in Margate, UK.

Part of Charles River Laboratories International, Inc., BioFocus DPI (Holdings) Ltd. functions as an investment holding British company. The company is based in Margate, UK.

Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands.

Founded in 2017, Wintringham Newco2 Ltd. is a holding British company that operates subsidiaries focused on property development. The company is based in Oxford, UK and is part of Nuffield Dominions Trust.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.

BioFocus DPI AG provides research and development services. The private company is based in Allschwill, Switzerland and has subsidiaries in Germany.